My research interests primarily focus on breast cancer, lung cancer and early drug development.
A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med (2014) 12(1):93. PMID: 24898705
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 15(5):R92. PMID: 24286369
A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol (2014) 25(2):505-11. PMID: 24368401
A Phase I dose escalation study to determine the optimal biological dose of irosustat – an oral steroid sulfatase inhibitor – in postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treatment (2013) 140(1):73-82. PMID: 23797179
Cancer Immune Therapy
I lead the cancer immunotherapy group at Barts with Professor Thomas Powles, overseeing clinical and translational research on immune checkpoint inhibitors and other immune strategies. The group currently runs more than 10 early clinical trials of single agent or combination cancer immunotherapy treatments, focusing on breast, genitourinary and thoracic cancers.
We are now researching epigenetic 'signatures' of different cancers in order to treat patients with the right medicine for their specific disease. We focus on the role of epigenetics in therapeutic resistance. The aim is to match medicines to patients and reduce the number of patients needlessly subjected to uncomfortable side effects. During this genetic and epigenetic mapping, we also aim to find new cancer-specific targets for drug development.
Novel DNA Damage and Stability Biomarkers and Therapeutic Targets
Over the next 5 years, a variety of novel DDR and chromatin maintenance mechanisms will be validated and, in collaboration with the newly appointed Chairs in Drug Discovery and Medicinal Chemistry, potential inhibitors for synthetic lethality strategies will be identified.
Trials Targeting Therapeutic Resistance
Two international window-of-opportunity trials that Professor Schmid leads focus on establishing the role of targeting the androgen receptor (AR) in early breast cancer, using the novel anti-androgen Enzalutamide:
I also lead a national clinical trial that investigates whether the addition of the HSP27-targeting antisensce oligoneucleotide Apatorsen to chemotherapy can improve the outcome of patients with squamous cell lung cancers.
These trials are supported by NIHR and CRUK funding to the Barts/Brighton Experimental Cancer Medicine Centre. UK recruitment is also supported by the NIHR Cancer Research Network and the UK Experimental Cancer Medicine Centre network.
Our international collaborative group studies circulating biomarkers for screening, diagnosis, patient management and surveillance of breast cancers. The programme includes: